A Phase 1b, Randomized, Double-blind (Sponsor-open), Placebo-controlled, Parallel Group Study To Assess The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Multiple Oral Doses Of Pf- 06865571 For 2 Weeks In Adults With Nonalcoholic Fatty Liver Disease
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2018
At a glance
- Drugs PF 06865571 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Pfizer
- 04 Dec 2018 Status changed from suspended to recruiting.
- 05 Nov 2018 Status changed from recruiting to suspended as sponsor elected to voluntarily pause study.
- 21 Jun 2018 Status changed from not yet recruiting to recruiting.